KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Income from Continuing Operations (2016 - 2025)

BeOne Medicines (ONC) has disclosed Income from Continuing Operations for 11 consecutive years, with 243166000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 260.1% to 243166000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 463597000.0, a 171.9% increase, with the full-year FY2025 number at 459407000.0, up 171.25% from a year prior.
  • Income from Continuing Operations was 243166000.0 for Q4 2025 at BeOne Medicines, up from 124841000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 243166000.0 in Q4 2025 to a low of 605856000.0 in Q4 2021.
  • A 5-year average of 224294550.0 and a median of 299790500.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 753.09% in 2022, then soared 260.1% in 2025.
  • BeOne Medicines' Income from Continuing Operations stood at 605856000.0 in 2021, then skyrocketed by 33.66% to 401899000.0 in 2022, then rose by 8.55% to 367553000.0 in 2023, then surged by 58.68% to 151881000.0 in 2024, then skyrocketed by 260.1% to 243166000.0 in 2025.
  • Per Business Quant, the three most recent readings for ONC's Income from Continuing Operations are 243166000.0 (Q4 2025), 124841000.0 (Q3 2025), and 94320000.0 (Q2 2025).